Skip to main content
4DMEDICAL LIMITED logo

4DMEDICAL LIMITED — Investor Relations & Filings

Ticker · 4DX ISIN · AU0000095416 LEI · 9845000A8F12A6A6FD75 ASX Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 546 across all filing types
Latest filing 2025-04-10 Regulatory Filings
Country AU Australia
Listing ASX 4DX

About 4DMEDICAL LIMITED

https://4dmedical.com/

4DMedical Limited develops non-invasive respiratory imaging solutions centered on its proprietary XV Technology. This platform utilizes advanced algorithms to transform standard X-ray sequences into four-dimensional quantitative data, visualizing regional lung function in motion. The flagship XV Lung Ventilation Analysis Software (XV LVAS) provides clinicians with detailed maps of airflow distribution throughout the respiratory cycle, facilitating the early detection and monitoring of chronic conditions such as COPD, asthma, and interstitial lung disease. By providing objective, high-resolution insights into lung ventilation without the limitations of traditional pulmonary function tests, the company's cloud-based diagnostic tools aim to improve clinical workflows and patient management. The integration of artificial intelligence further enhances its capability to deliver precise, automated lung tissue analysis.

Recent filings

Filing Released Lang Actions
Notification of cessation of securities - 4DX 6 pages 19.9KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and contains detailed information about securities that have ceased, including ASX security codes, descriptions, numbers of securities ceased, reasons for cessation, and dates. It is a formal announcement to the ASX regarding the lapse or expiry of options and securities. There is no financial performance data, management discussion, or report content. The document is a regulatory announcement about changes in the company's issued securities, specifically cessation of securities. This fits the category of Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit into more specific categories like capital changes or director dealings, since it reports cessation of securities rather than new issuance or buybacks.
2025-04-10 English
4DMedical wins industry partners and discussed in Congress 4 pages 362.9KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 10 April 2025 from 4DMedical Limited. It details new contracts with industry partners for clinical trials using 4DMedical's imaging technology and highlights the company's mention in US Congressional testimony. The content focuses on business developments, partnerships, and commercial strategy rather than financial results or regulatory filings. There are no financial statements, earnings data, or detailed management analysis. The document is a corporate announcement about contracts and strategic partnerships, not a financial report or regulatory filing. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to new contracts and commercial developments that impact the company's capital and business growth.
2025-04-09 English
Letter to Shareholders, Notice of EGM & Proxy Form 27 pages 748.4KB
Proxy Solicitation & Information Statement Classification · 100% confidence The document is an ASX announcement dated 1 April 2025 from 4DMedical Limited regarding an Extraordinary General Meeting (EGM) scheduled for 1 May 2025. It includes a Notice of Meeting, Proxy Form, Chair's letter, and detailed resolutions to be voted on at the EGM. The content focuses on informing shareholders about the meeting, how to vote, and the business to be conducted, including ratification and approval of share and option issues. There are no financial statements, earnings data, or management discussion of financial results. The document is a formal meeting notice and related materials, not a report or transcript. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI), which covers materials sent to shareholders to provide information and request votes for meetings, including EGMs.
2025-03-31 English
Cost reduction program delivers $6.5m in annualised savings 3 pages 211.8KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 26 March 2025 from 4DMedical Limited. It details a cost reduction program delivering $6.5 million in annualized savings, completion of a capital raise of $13.9 million, and changes in company secretary and CFO. The content focuses on operational updates, financial strategy, and management changes but does not contain detailed financial statements or comprehensive financial performance data. It is not a full annual or interim report, nor an earnings release. The document is a corporate announcement about cost savings, capital raising, and management changes. Therefore, it fits best under Capital/Financing Update (CAP) due to the capital raise and cost-saving program announcements, and also includes management changes but the primary focus is on financing and cost reduction. Confidence is high given the clear focus on capital raising and cost reduction measures.
2025-03-25 English
4DMedical completes oversubscribed $8.4m SPP 3 pages 215.5KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 25 March 2025 regarding the completion of an oversubscribed $8.4 million Securities Purchase Plan (SPP) by 4DMedical. It details the capital raising activities including the SPP and a prior placement, the number of shares issued, pricing, and intended use of proceeds. The document focuses on fundraising and capital structure changes, with no financial statements or detailed financial performance data. It is not a full financial report, earnings release, or management discussion. The content aligns with updates on company fundraising and capital structure changes, which fits the Capital/Financing Update (CAP) category. The document length (6714 characters) and content confirm it is a full announcement, not a brief report publication notice or regulatory filing. Therefore, the appropriate classification is CAP with high confidence.
2025-03-24 English
Application for quotation of securities - 4DX 7 pages 19.7KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 2A - Application for quotation of securities' and is an official announcement from 4DMEDICAL LIMITED regarding the application for quotation of securities on the ASX. It details the number and type of securities to be quoted, issue dates, and related information. This type of document is a formal regulatory announcement related to securities quotation and capital changes, not a financial report or earnings release. It is not a report itself but an announcement of a capital market action. Therefore, it fits best under the category of Share Issue/Capital Change (SHA). The document length and content confirm it is not a brief notice but a detailed application for quotation, consistent with SHA filings.
2025-03-24 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.